Clinical Research Directory

Inclusion Criteria: 1. Histologically or cytologically confirmed recurrent or metastatic solid tumors; 2. Patients who have failed standard or conventional treatment or for whom no standard treatment is available( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment); 3. Participants with advanced recurrent, unresectable, and/or metastatic tumors must have evaluable or measurable lesions (according to RECIST 1.1)； 4. Eastern Cooperative Oncology Group performance status score of 0 or 1; 5. Life expectancy \> 12 weeks; 6. Adequate bone marrow, renal, and hepatic function; 7. Patients should participate in the study voluntarily and sign informed consent. Exclusion Criteria: 1. Any patient who is known to have untreated central nervous system (CNS) metastasis; 2. Other kinds of malignancies within 5 years; 3. Gastrointestinal abnormalities; 4. Cardiovascular and cerebrovascular diseases; 5. Involved in other clinical trials within 4 weeks before enrollment; 6. Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment; 7. Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment; 8. Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1; 9. Severe infection within 4 weeks prior to enrollment; 10. Uncontrolled massive ascites, pleural or pericardial effusion； 11. Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy; 12. Prior therapies with KAT6 inhibitors 13. Pregnant or lactating women; 14. Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study. 15. Other patients are not eligible for enrollment assessed by investigators.